Pandrug-Resistant Acinetobacter baumannii Causing Nosocomial Infections in a University Hospital, Taiwan

The rapid emergence (from 0% before 1998 to 6.5% in 2000) of pandrug-resistant Acinetobacter baumannii (PDRAB) was noted in a university hospital in Taiwan. To understand the epidemiology of these isolates, we studied 203 PDRAB isolates, taken from January 1999 to April 2000: 199 from 73 hospitalized patients treated at different clinical settings in the hospital and 4 from environmental sites in an intensive-care unit. Pulsed-field gel electrophoresis analysis and random amplified polymorphic DNA (RAPD) generated by arbitrarily primed polymerase chain reaction of these 203 isolates showed 10 closely related genotypes (10 clones). One (clone 5), belonging to pulsotype E and RAPD pattern 5, predominated (64 isolates, mostly from patients in intensive care). Increasing use of carbapenems and ciprofloxacin (selective pressure) as well as clonal dissemination might have contributed to the wide spread of PDRAB in this hospital.

[1]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[2]  P. Hsueh,et al.  Current Status of Antimicrobial Resistance in Taiwan , 2002, Emerging infectious diseases.

[3]  J. Wu,et al.  Metallo-β-Lactamases in ClinicalPseudomonas Isolates in Taiwan and Identification of VIM-3, a Novel Variant of the VIM-2 Enzyme , 2001, Antimicrobial Agents and Chemotherapy.

[4]  J. Ariza,et al.  Emergence and Rapid Spread of Carbapenem Resistance during a Large and Sustained Hospital Outbreak of MultiresistantAcinetobacter baumannii , 2000, Journal of Clinical Microbiology.

[5]  G. Bou,et al.  Characterization of a Nosocomial Outbreak Caused by a Multiresistant Acinetobacter baumannii Strain with a Carbapenem-Hydrolyzing Enzyme: High-Level Carbapenem Resistance inA. baumannii Is Not Due Solely to the Presence of β-Lactamases , 2000, Journal of Clinical Microbiology.

[6]  Ronald N. Jones,et al.  MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. , 2000, The Journal of antimicrobial chemotherapy.

[7]  Nnis System,et al.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System. , 1999, American journal of infection control.

[8]  R. Gaynes,et al.  Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  L. Peixe,et al.  Emergence of Carbapenem-Hydrolyzing Enzymes inAcinetobacter baumannii Clinical Isolates , 1999, Journal of Clinical Microbiology.

[10]  A. Kapil,et al.  In Vitro Activities of Ampicillin-Sulbactam and Amoxicillin-Clavulanic Acid against Acinetobacter baumannii , 1998, Journal of Clinical Microbiology.

[11]  Pan‐Chyr Yang,et al.  Persistence of a Multidrug-ResistantPseudomonas aeruginosa Clone in an Intensive Care Burn Unit , 1998, Journal of Clinical Microbiology.

[12]  D. Livermore,et al.  Worldwide emergence of carbapenem-resistant Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.

[13]  M. Jacobs,et al.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies , 1997, Antimicrobial agents and chemotherapy.

[14]  K. Waites,et al.  Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations , 1997, Antimicrobial agents and chemotherapy.

[15]  R. Clárk,et al.  Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa outer membrane protein. , 1996, The Journal of antimicrobial chemotherapy.

[16]  F. J. Caballero,et al.  Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Rybak,et al.  Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa , 1996, Antimicrobial agents and chemotherapy.

[18]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[19]  B. Kreiswirth,et al.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam , 1994, The Lancet.

[20]  J. Duval,et al.  Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods , 1994, Journal of clinical microbiology.

[21]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[22]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[23]  J. Klastersky,et al.  Significance of antimicrobial synergism for the outcome of gram negative sepsis. , 1977, The American journal of the medical sciences.

[24]  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.

[25]  P. Hsueh,et al.  Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. , 2002, The Journal of antimicrobial chemotherapy.

[26]  P. Hsueh,et al.  Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. , 2002, Emerging infectious diseases.

[27]  J. Wu,et al.  Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. , 2001, Microbial drug resistance.

[28]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[29]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .